NASDAQ OMX (NASDAQ:NDAQ) announced that Recipharm AB (short name: RECI B), a Mid Cap company within the Healthcare sector, today started trading of its shares on the main market of NASDAQ OMX Stockholm. Recipharm is the sixth company to list at NASDAQ OMX’s Nordic main markets in 2014 (NASDAQ OMX Stockholm; Helsinki; Copenhagen and Iceland).
Recipharm is one of Europe’s leading pharmaceutical Contract Development and Manufacturing Organisations (CDMO). Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms including solid dose, semi solids, steriles (liquids and freeze dried), beta-lactams, hormones, dry powder metered dose inhalers, oral liquids and granulates, from facilities across Europe. Headquartered in Sweden, Recipharm employs some 1,500 employees and with a sales turnover in excess of SEK 2.1 bn. The company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain.
“Today marks the beginning of a new phase in Recipharm’s life. We welcome all our new shareholders who have demonstrated their confidence in the company and its strategy for growth,” said Thomas Eldered, CEO of Recipharm. “As a listed company with a new access to the capital markets, I am confident that Recipharm now will be able to even more forcefully participate in the consolidation of the CMDO market.”
“We congratulate Recipharm on their IPO and welcome them to NASDAQ OMX and our healthcare sector,” said Adam Kostyal, Senior Vice President at NASDAQ OMX. “We continue to see significant interest among healthcare companies looking to raise captal in the public market, and Recipharm’s listing today underlines that trend.”